نتایج جستجو برای: codon 12 and 13

تعداد نتایج: 16938062  

2014
D Dinu M Dobre E Panaitescu R Bîrlă C Iosif P Hoara A Caragui M Boeriu S Constantinoiu C Ardeleanu

OBJECTIVE The prognostic significance of KRAS gene mutations, evaluated by using two methods in patients with colorectal cancer (CRC). MATERIAL AND METHODS Retrospective study involving 58 patients diagnosed with CRC and treated between 2003 and 2010 in the General and Esophageal Surgery Clinic of "Sf. Maria" Hospital, Bucharest. The macroscopic and microscopic examination of the resected spe...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Christoph P Dieterle Michael Conzelmann Ulrich Linnemann Martin R Berger

The aim of this study was to identify K-ras mutations as marker for isolated tumor cells in liver, lymph node, and bone marrow specimens of colorectal cancer patients. To detect these, a PCR-RFLP assay was used with a sensitivity exceeding that of routine histopathology by at least 1 order of magnitude. In addition, the ratio of mutated versus wild-type alleles was determined by an internal sta...

Journal: :Cancer research 1990
T Enomoto M Inoue A O Perantoni N Terakawa O Tanizawa J M Rice

The role of cellular oncogenes in the development of epithelial tumors of the human female reproductive tract has not previously been extensively studied. DNAs isolated from ten human uterine, 13 ovarian, and four cervical neoplasms and from three cell lines derived from endometrial adenocarcinoma were investigated by dot blot hybridization after polymerase chain reaction amplification of ras g...

2014
Joanna HM Tong Raymond WM Lung Frankie MC Sin Peggy PY Law Wei Kang Anthony WH Chan Brigette BY Ma Tony WC Mak Simon SM Ng Ka Fai To

KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization of rare insertion mutations within the functional domain of KRAS. KRAS mutations are found in 44.5...

2012
Yu Imamura Teppei Morikawa Xiaoyun Liao Paul Lochhead Aya Kuchiba Mai Yamauchi Zhi Rong Qian Reiko Nishihara Jeffrey A. Meyerhardt Kevin M. Haigis Charles S. Fuchs Shuji Ogino Frank Knox

1 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; 2 Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA; 3 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; 4 Department of Pathology, Brigham and Women’s Hospital, and Harvard ...

Journal: :The American journal of pathology 1995
R F Caduff C M Johnston T S Frank

Mutations of the Ki-ras oncogene in endometrial carcinoma have been reported in Japan, but the prevalence and clinical significance of such mutations in the United States remains unclear. DNA extracted from paraffin sections of 112 carcinomas of the endometrium was amplified by the polymerase chain reaction with mismatched primers that generated a BstNI recognition site with the wild-type codon...

2006
Jean-Sébastien Hoffmann Michael Fry Jiuping Ji Jean-Sébastien Hoffmann Kandace J. Williams Lawrence A. Loeb Joseph Gottstein

Mutagenesis of protooncogenes has been postulated to contribute to the initiation and progression of human cancer. Activating mutations in the H-ras gene are predominantly single-base substitutions and are most fre quently identified at codons 12, 13, and 61. We have analyzed the effects of DNA sequence context at specific codons that are hot spots for raj mutation with respect to abnormalities...

رودباری, فاطمه, شیخ سفلی, فاطمه, قدیانی, مجتبی, پوپک, بهزاد,

Background: Kirsten rat sarcoma (KRAS) gene is a target of genetic alterations which are diagnostic and prognostic biomarkers in patients with metastatic colorectal cancer who are treated with monoclonal anti-EGFR antibodies such as cetuximab and panitumumab. KRAS mutations are seen in 35-42% of patients with colorectal cancer. The high frequency of these mutations in colorectal cancer represen...

Journal: :Pathobiology : journal of immunopathology, molecular and cellular biology 2014
Natsuko Saito Shigeki Tomita Kazuhito Ichikawa Hiroyuki Mitomi Johji Imura Takahiro Fujimori

OBJECTIVE Colorectal cancer patients bearing wild-type KRAS benefit from anti-epidermal growth factor receptor (EGFR) antibody treatment. Since clinical studies showed the efficacy of anti-EGFR antibody treatment for metastatic colorectal cancer (mCRC), we analyzed KRAS mutations in mCRC to gain insight into the association between these mutations and clinicopathological characteristics. METH...

Journal: :The Journal of urology 2009
I Boulalas A Zaravinos I Karyotis D Delakas D A Spandidos

PURPOSE Bladder cancer is the fifth most common malignancy in men in Western society. We determined RAS codon 12 and 13 point mutations and evaluated mRNA expression levels in transitional cell carcinoma cases. MATERIALS AND METHODS Samples from 30 human bladder cancers and 30 normal tissues were analyzed by polymerase chain reaction/restriction fragment length polymorphism and direct sequenc...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید